Improved survival outcomes in cancer patients with hereditary hemorrhagic telangiectasia

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 1, 2014, Pages 117-125

  Duarte, Christine W ^a   Murray, Kimberly ^a   Lucas, F Lee ^a   Fairfield, Kathleen ^a   Miller, Heather ^a   Brooks, Peter ^a   Vary, Calvin P H ^a  

^a Maine Medical Center Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOGLIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; COHORT ANALYSIS; COLORECTAL CANCER; FEMALE; GENETIC DISORDER; HUMAN; KAPLAN MEIER METHOD; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOMES RESEARCH; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RENDU OSLER WEBER DISEASE; RETROSPECTIVE STUDY; SURVIVAL RATE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; NEOPLASMS; RETROSPECTIVE STUDIES; SEER PROGRAM; SURVIVAL ANALYSIS; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; TREATMENT OUTCOME; UNITED STATES;

EID: 84892753418     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0665     Document Type: Article

References (44)

1. Arthur HM, Ure J, Smith AJ, Renforth G, Wilson DI, Torsney E, et al. Endoglin, an ancillary TGF-b receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev Biol 2000;217:42-53.
2. Bourdeau A, Faughnan ME, Letarte M. Endoglin-deficient mice, a unique model to study hereditary hemorrhagic telangiectasia. Trends Cardiovasc Med 2000;10:279-85.
3. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG, et al. Defective angiogenesis in mice lacking endoglin. Science 1999;284: 1534-7.
4. Rosen LS, Hurwitz HI, Wong MK, Goldman J, Mendelson DS, Figg WD, et al. A phase I first-in-human study of TRC105 (Anti-endoglin antibody) in patients with advanced cancer. Clin Cancer Res 2012;18: 4820-9.
5. Barbara NP, Wrana JL, Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-b superfamily. J Biol Chem 1999; 274:584-94.
6. Blanco FJ, Santibanez JF, Guerrero-Esteo M, Langa C, Vary CP, Bernabeu C. Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex. J Cell Physiol 2005;204: 574-84.
7. Scherner O, Meurer SK, Tihaa L, Gressner AM, Weiskirchen R. Endoglin differentially modulates antagonistic transforming growth factor-b1 and BMP-7 signaling. J Biol Chem 2007;282: 13934-43.
8. Bourdeau A, Dumont DJ, Letarte M. A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 1999;104:1343-51.
9. El-Gohary YM, Silverman JF, Olson PR, Liu YL, Cohen JK, Miller R, et al. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. Am J Clin Pathol 2007;127:572-9.
10. Saad RS, Liu YL, Nathan G, Celebrezze J, Medich D, Silverman JF. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol 2004;17:197-203.
11. Smith SJ, Tilly H, Ward JH, Macarthur DC, Lowe J, Coyle B, et al. CD105 (Endoglin) exerts prognostic effects via its role in the microvascular niche of paediatric high grade glioma. Acta Neuropathol 2012;124:99-110.
12. Kassouf W, Ismail HR, Aprikian AG, Chevalier S. Whole-mount prostate sections reveal differential endoglin expression in stromal, epithelial, and endothelial cells with the development of prostate cancer. Prostate Cancer Prostatic Dis 2004;7:105-10.
13. Wikstrom P, Lissbrant IF, Stattin P, Egevad L, Bergh A. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 2002;51:268-75.
14. Gomez-Esquer F, Agudo D, Martinez-Arribas F, Nunez-Villar MJ, Schneider J. mRNA expression of the angiogenesis markers VEGF and CD105 (endoglin) in human breast cancer. Anticancer Res 2004;24:1581-5.
15. Takase Y, Kai K, Masuda M, Akashi M, Tokunaga O. Endoglin (CD105) expression and angiogenesis status in small cell lung cancer. Pathol Res Pract 2010;206:725-30.
16. Minhajat R, Mori D, Yamasaki F, Sugita Y, Satoh T, Tokunaga O. Endoglin (CD105) expression in angiogenesis of colon cancer: analysis using tissue microarrays and comparison with other endothelial markers. Virchows Arch 2006;448:127-34.
17. Bernabeu C, Lopez-Novoa JM, Quintanilla M. The emerging role of TGF-b superfamily coreceptors in cancer. Biochim Biophys Acta 2009;1792:954-73.
18. Perez-Gomez E, Del Castillo G, Juan Francisco S, Lopez-Novoa JM, Bernabeu C, Quintanilla M. The role of the TGF-beta coreceptor endoglin in cancer. Sci World J 2010;10:2367-84.
19. Liu Y, Jovanovic B, Pins M, Lee C, Bergan RC. Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion. Oncogene 2002;21:8272-81.
20. Lakshman M, Huang X, Ananthanarayanan V, Jovanovic B, Liu Y, Craft CS, et al. Endoglin suppresses human prostate cancer metastasis. Clin Exp Metastasis 2011;28:39-53.
21. Craft CS, Romero D, Vary CP, Bergan RC. Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway. Oncogene 2007;26:7240-50.
22. Romero D, Terzic A, Conley BA, Craft CS, Jovanovic B, Bergan RC, et al. Endoglin phosphorylation by ALK2 contributes to the regulation of prostate cancer cell migration. Carcinogenesis 2010;31: 359-66.
23. Romero D, O'Neill C, Terzic A, Contois L, Young K, Conley BA, et al. Endoglin regulates cancer-stromal cell interactions in prostate tumors. Cancer Res 2011;71:3482-93.
24. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, et al. Endoglin, a TGF-b binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet. 1994;8:345-51.
25. Saluja S, White RI. Hereditary hemorrhagic telangiectasia of the liver: hyperperfusion with relative ischemia-poverty amidst plenty. Radiology 2004;230:25-7.
26. Sabba C, Gallitelli M, Pasculli G, Suppressa P, Resta F, Tafaro GE. HHT: a rare disease with a broad spectrum of clinical aspects. Curr Pharm Des 2006;12:1217-20.
27. Sabba C, Pasculli G, Lenato GM, Suppressa P, Lastella P, Memeo M, et al. Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers. J Thromb Haemost 2007;5:1149-57.
28. Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000;91:66-7.
29. Zippin C, Lum D, Hankey BF. Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer 1995;76:2343-50.
30. Nattinger AB, McAuliffe TL, Schapira MM. Generalizability of the surveillance, epidemiology, and end results registry population: factors relevant to epidemiologic and health care research. J Clin Epidemiol 1997;50:939-45.
31. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002;40: IV-3-18.
32. Klabunde CN, Warren JL, Legler JM. Assessing comorbidity using claims data: an overview. Med Care 2002;40:IV-26-35.
33. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9.
34. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
35. van Gent MW, Velthuis S, Post MC, Snijder RJ, Westermann CJ, Letteboer TG, et al. Hereditary hemorrhagic telangiectasia: how accurate are the clinical criteria? Am J Med Genet A 2013;161:461-6.
36. Kaltenboeck A, Johnson SJ, Davis MR, Birnbaum HG, Carroll CA, Tarrants ML, et al. Direct costs and survival of medicare beneficiaries with early and advanced Parkinson's disease. Parkinsonism Relat Disord 2012;18:321-6.
37. Cox DR, Oakes D. Analysis of survival data. London: Chapman & Hall; 1984.
38. Collett D. Modelling survival data in medical research. London: Chapman & Hall; 1994.
39. Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc 2009;172: 137-59.
40. Knapp G, Hartung J. Improved tests for a random effects metaregression with a single covariate. Stat Med 2003;22:2693-710.
41. Zarrabeitia R, Albinana V, Salcedo M, Senaris-Gonzalez B, Fernandez-Forcelledo JL, Botella LM. A review on clinical management and pharmacological therapy on hereditary haemorrhagic telangiectasia (HHT). Curr Vasc Pharmacol 2010;8:473-81.
42. Cole SG, Begbie ME, Wallace GM, Shovlin CL. A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet 2005;42:577-82.
43. Harrell FE Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87.
44. Casey TM, Eneman J, Crocker A, White J, Tessitore J, Stanley M, et al. Cancer associated fibroblasts stimulated by transforming growth factor-b1 (TGF-b1) increase invasion rate of tumor cells: a population study. Breast Cancer Res Treat 2008;110:39-49.